Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Outlook 2025–2035
The Minimally Invasive Glaucoma Surgery (MIGS) Devices Market was USD 586.3 Million in 2024 and is expected to grow to USD 1,045.6 Million by 2035 while rising at a rate of about 5.4% from 2025 to 2035. Growth in the market is fueled by more cases of glaucoma worldwide and people’s increasing desire for noninvasive surgeries. Clinicians turn to MIGS devices more and more, as they help treat glaucoma while creating fewer problems and shortening the recovery period.
Request Sample-https://www.metatechinsights.c....om/request-sample/12
The Market
MIGS implants and devices are used to lower eye pressure and treat glaucoma using small incisions and simple procedures. Thanks to these robots, surgeries take less time, they damage less tissue and patients recover more rapidly. The aim of the market is to deliver glaucoma therapies that improve a patient’s condition and lower risks involved with surgery. As people become more aware of eye care worldwide and early diagnosis improves, more MIGS procedures are being adopted in various economies.
Important reasons driving the market
1. Glaucoma is becoming more common in other countries.
The World Health Organization says that glaucoma accounts for 12 percent of blindness across the globe. Because there are more older adults in North America and Europe, glaucoma cases have been increasing steadily. As a result, more people are choosing advanced surgical devices for glaucoma, since they help avoid difficulties that may come with traditional treatments. Consequently, more patients with early glaucoma are now using MIGS devices.
Stents Segment Overview
Stents are the most popular devices due to their role in helping aqueous humor leave the eye and decrease intraocular pressure. Since these devices are made with biocompatible substances, surgeons can place them efficiently during a cataract operation. Rising rates of cataract-glaucoma surgeries are increasing the need for glaucoma drainage stents.
Full Report-https://www.metatechinsights.c....om/industry-insights
Trabecular Meshwork Bypass Segment
Trabecular meshwork bypass devices help reduce the eye’s fluid by addressing the natural drainage channel. The segment is expanding fast as it proves to be effective for early to moderate glaucoma and is less invasive. Using this procedure, doctors bypass the obstruction in the trabecular meshwork to reduce the pressure inside the eye, making the treatment preferable for ophthalmologists.
North America Market
In North America, MIGS devices are very popular due to the country’s highly developed healthcare system, great awareness about healthcare and equitable reimbursement policies. The area has a large number of older people who could encounter glaucoma, prompting a need for safe glaucoma treatments. Market growth is being driven by advances in technology and new products that the FDA approves.
Buy Now-https://www.metatechinsights.com/checkout/1204
Global Competitive Landscape
The global MIGS devices market is highly competitive, with key players including Glaukos Corporation, Alcon Inc., Ivantis Inc. (a subsidiary of Alcon), Sight Sciences, and Santen Pharmaceutical Co., Ltd. These companies focus on product innovation, clinical research, and strategic collaborations to strengthen their market presence. Expansion into emerging markets, robust distribution networks, and investments in surgeon training are among the core strategies driving their global growth.
